Ascentage Pharma Group International Stock price

Equities

6855

KYG0519B1023

Biotechnology & Medical Research

Delayed Hong Kong S.E. 01:53:44 2024-02-28 am EST 5-day change 1st Jan Change
25.35 HKD -2.50% Intraday chart for Ascentage Pharma Group International -0.20% -7.14%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site

Financials

Sales 2023 * 385M 53.44M 418M Sales 2024 * 535M 74.29M 581M Capitalization 6.81B 946M 7.4B
Net income 2023 * -839M -117M -912M Net income 2024 * -749M -104M -814M EV / Sales 2023 * 17.7 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 12.7 x
P/E ratio 2023 *
-8.2 x
P/E ratio 2024 *
-9.26 x
Employees 565
Yield 2023 *
-
Yield 2024 *
-
Free-Float 73.35%
More Fundamentals * Assessed data
Dynamic Chart
Ascentage Pharma's Phase 3 Trial for Chronic Myeloid Leukemia Treatment Gets US FDA Nod; Shares Rise 3% MT
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia CI
Ascentage Pharma Trustee Buys 100,000 Shares MT
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network CI
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib CI
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR CI
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication CI
China Approves Ascentage Pharma's Chronic-Phase Chronic Myeloid Leukemia Treatment MT
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients CI
Ascentage Pharma Group Trustee Purchases 100,000 Shares Under Restricted Share Scheme MT
Ascentage Pharma Trustee Repurchases Shares MT
Ascentage Pharma Trustee Buys 50,000 Shares Under Restricted Share Scheme MT
Ascentage Pharma to Present Clinical Data on Hematological Drugs in US Meet MT
Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM CI
Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports CI
More news
1 day-2.50%
1 week-0.20%
Current month+10.22%
1 month+5.85%
3 months+1.00%
6 months+3.89%
Current year-7.14%
More quotes
1 week
24.80
Extreme 24.8
27.15
1 month
20.75
Extreme 20.75
27.15
Current year
20.75
Extreme 20.75
28.00
1 year
18.54
Extreme 18.54
28.15
3 years
11.16
Extreme 11.16
58.20
5 years
11.16
Extreme 11.16
58.20
10 years
11.16
Extreme 11.16
58.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 09-04-30
Founder 67 09-04-30
Director of Finance/CFO 40 21-11-28
Members of the board TitleAgeSince
Director/Board Member 64 21-03-30
Director/Board Member 60 17-11-16
Director/Board Member 52 19-06-12
More insiders
Date Price Change Volume
24-02-28 25.35 -2.50% 1 902 074
24-02-27 26 +3.59% 959,200
24-02-26 25.1 -1.57% 1,176,860
24-02-23 25.5 -0.20% 495,800
24-02-22 25.55 +0.59% 557,600

Delayed Quote Hong Kong S.E., February 28, 2024 at 01:53 am EST

More quotes
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
23.92 CNY
Average target price
29.67 CNY
Spread / Average Target
+24.04%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Ascentage Pharma Group International - Hong Kong S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW